BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) recovered 150.99% of its value since hitting low of $3.04. The recent move of 14.39% gain helped the stock to close at $7.63 when trading ended on Sep. 13, 2017. At recent session, the prices were hovering between $7.23 and $8.5. This company shares are 96.59% off its target price of $15 and the current market capitalization stands at $1.37B. The recent change has given its price a -9.95% deficit over SMA 50 and -29.02% deficit over its 52-week high. The stock witnessed -7.33% declines, -0.39% declines and 40.77% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BVXV’s volatility during a week at 11.34% and during a month it has been found around 5.52%.

BiondVax Pharmaceuticals Ltd. 13F Filings

At the end of 6/30/2017 reporting period, 2 institutional holders increased their position in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) by some 897 shares, 5 decreased positions by 55,219 and 2 held positions by -37,596. That puts total institutional holdings at 18,520 shares, according to SEC filings. The stock grabbed 2 new institutional investments totaling 897 shares while 4 institutional investors sold out their entire positions totaling 54,919 shares.

BiondVax Pharmaceuticals Ltd. (BVXV) Analyst Guide

Not many analysts have released their opinion on BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.

Previous article11 hedge funds sold their entire positions in Alliqua BioMedical, Inc. (ALQA)
Next articleTravelCenters of America LLC (TA) has rebounded 49.15% since its low of $2.95